In a comprehensive video discussion with STAT, ADVI Health experts Caitlin Sheetz, head of strategic analytics, value and economics (SAVEs), and Pete Kardel, vice president of strategic analytics, value and economics (SAVEs), explore the profound, multi-year effects of recent and anticipated Centers for Medicare and Medicaid Services (CMS) policy shifts on the pharmaceutical industry.

The conversation delves into the most critical regulatory changes—including the implications of Medicare Part D reforms and the framework for drug price negotiation—that are fundamentally reshaping the market. Learn what the industry should expect in the coming months and years and gain essential strategic insights on how pharma companies—particularly those in oncology and specialty medicine—can best adapt their research, development, and commercialization strategies to thrive in this new environment.

Listen in or to read the full interview transcript